GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Not yet recruiting · NCT05303701 · Registry updated 2026-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 3 | 2026-06-10 | NCT05303701 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Samsung Pharmaceutical Co., Ltd. | 1 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||